RxDoctor Payments Data

Jacqueline Small

Family · Cumming, GANPI 1407415615

Payments from drug & device makers

$7,484in general payments, 2019–2025

Across 402 payments — averaging $18.62 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$1K
  • Lilly USA, LLC$732
  • AbbVie$647
  • Astellas Pharma US Inc$466
  • Otsuka America Pharmaceutical, Inc.$426
  • Pfizer$392
  • plus $4K from 41 others

What the payments were for

  • Food & beverage$7,35098%
  • Education$1342%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$7,484 in reported general payments places this provider in the 95th percentile of 6,258 family providers in Georgia.

See all family providers in Georgia

Medicare billing

Part B allowed, 2024
$56,598
Medicare patients
375
Services billed
1,088

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin53$54,895
JanuviaSitagliptin Phosphate26$29,403
FarxigaDapagliflozin Propanediol36$23,725
MounjaroTirzepatide22$23,287
EliquisApixaban22$20,885
Trelegy ElliptaFluticasone/Umeclidin/Vilanter24$17,780
OzempicSemaglutide16$15,181
GemtesaVibegron21$13,551
Breo ElliptaFluticasone/Vilanterol13$5,200
LexaproEscitalopram Oxalate17$4,800
Levothyroxine Sodium351$4,247
SymbicortBudesonide/Formoterol Fumarate12$4,156
Celecoxib14$2,917
SynthroidLevothyroxine Sodium20$2,376
Gabapentin134$2,212

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimJardiance$122$54,89553 claims
MerckJanuvia$12$29,40326 claims
AstraZenecaFarxiga, Symbicort$298$27,88148 claims
Lilly USA, LLCMounjaro$732$23,28722 claims
GSKTrelegy Ellipta, Breo Ellipta$383$22,98037 claims
PfizerEliquis$392$20,88522 claims
Novo NordiskOzempic$1,054$15,18116 claims
Sumitomo Pharma America, Inc.Gemtesa$99$13,55121 claims
AbbVieLexapro, Synthroid$647$7,17637 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 6,258 family providers in Georgia.

Other family in Cumming

See the full list for Georgia

Where these figures come from

Is this you, or does something look wrong? →